Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials

Abstract

Coagulopathic trauma patients appear to derive particular benefit from early adjunctive rFVIIa therapy.